Lycera Achieves First Milestone in Merck & Co., Inc. Research Collaboration

Published: Dec 21, 2011

ANN ARBOR, Mich.--(BUSINESS WIRE)--Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has reached the first milestone under its research collaboration with Merck, triggering a milestone payment. The collaboration is focused on developing drug candidates that have the potential to treat major autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis.

Back to news